PLAAT3 (Phospholipase A And Acyltransferase 3)

These results imply that PLA2G16-mediated C24:4 (n-6) accumulation in the lung acts as a metabolic disorder to CD8+ T cell antitumor activity and highlights a critical role of PLA2G16 in promoting TNBC lung metastasis. Targeting PLA2G16 and combination with anti-PD-1-based immunotherapy may be an effective strategy for clinical tumor immunotherapy.

PAC exerts anti-PCa effects by reprogramming lipid metabolism via multi-component targeting of PTDSS1/PLAAT3/PEMT/PLD4, thereby inhibiting proliferation, promoting apoptosis, and remodeling the TME. This study reveals a novel lipid-centric mechanism for PCa intervention using PAC.

Analysis of public LUSC data confirmed associations between the expression levels of genes encoding enzymes involved in the biosynthesis pathways of arginine, proline (ASL, OTC, PYCR2), PC (CEPT1, CHPT1, LPCAT1) and LPC (LCAT, PLA2G16, PLB1) with a 5-yr survival outcome. The observed metabolic reprogramming in LUSC patients suggested the potential utility of metabolites as a supportive biomarkers for LUSC diagnosis.

In all cases, GPT-RadPlan either outperformed or matched the clinical plans, demonstrating superior target coverage and reducing organ-at-risk doses by 5 Gy on average. Significance: Consistently satisfying the dose-volume objectives in the clinical protocol, GPT-RadPlan represents the first multimodal large language model agent that mimics the behaviors of human planners in radiation oncology clinics, achieving promising results in automating the treatment planning process without the need for additional training.

PLA2G16 expression was linked to specific immune infiltration patterns and cancer-related molecular pathways. Elevated PLA2G16 expression is associated with poor survival and gemcitabine resistance in pancreatic cancer, making it a potential prognostic marker and therapeutic target.

Moreover, DPP7 silencing attenuates epithelial-mesenchymal transition, as evidenced by the upregulation of E-cadherin and downregulation of N-cadherin, Vimentin, and Snail. In conclusion, this study establishes an LRG-based model for COAD prognostic prediction and nominates DPP7 as a promising therapeutic target for COAD treatment.

This study revealed the frequency and prognosis of locally advanced maxillary sinus cancer fed from the ICA. The prognosis was equivalent between cases with or without feeding from the ICA; therefore, it would be considered important to determine the tumor volume for each feeding blood vessel and assess the areas of dual perfusion.

RADPLAT provides superior local control and survival outcomes compared to IV-CRT for T4 OPC, with comparable safety and functional preservation. These findings suggest that RADPLAT may be a promising alternative to IV-CRT for cases with T4 OPC.

The prognosis of RADPLAT was favorable after 5-year follow-up with acceptable late adverse events and low proportion of treatment related death.

Most importantly, PLAG4B was independently related to longer disease-free survival. This is the first study exploring comprehensively the expression levels of PLA2 in PCa, showing that the higher expression of some PLA2 should be used as biomarkers of good prognosis and longer disease-free survival.

The m-RADPLAT regimen yielded favorable survival rates and clinical outcomes in patients with impaired renal function.

Further experiments revealed that the overexpression of YAP partially reversed the inhibitory effects of PLA2G16 silence on multiple myeloma cell malignant development and the reprogramming of glucose metabolism. Collectively, PLA2G16 silence impeded multiple myeloma progression and inhibited glucose metabolism reprogramming by blocking the Hippo/YAP signaling pathway.